Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Apogee Therapeutics Inc (OQ:APGE)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 221 Crescent St.
Building 17, Suite 102b
WALTHAM MA 02453
Tel: N/A
Website: https://apogeetherapeutics.com
IR: See website
Key People
Mark C. McKenna
Chairman of the Board
Michael Henderson
Chief Executive Officer, Director
Jane Pritchett Henderson
Chief Financial Officer
Carl Dambkowski
Chief Medical Officer
   
Business Overview
N/A
Financial Overview
For the fiscal year ended 31 December 2023, Apogee Therapeutics Inc revenues was not reported. Net loss increased from $39.8M to $84M. Higher net loss reflects biotechnology segment loss increase from $30.7M to $93M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.84 to -$1.74.